Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
Angela J. Okragly, Aya Ryuzoji, Isabella H. Wulur, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 7, pp. 1535-1547
Open Access | Times Cited: 15

Showing 15 citing articles:

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access | Times Cited: 2
Lebrikizumab: First Approval
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 3, pp. 347-353
Closed Access | Times Cited: 7
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Diana Bernardo, Thomas Bieber, Tiago Torres
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 753-764
Open Access | Times Cited: 16
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment
Joe Gorelick, Andrea Nguyen, Shannon Schneider, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Development of an mPBPK machine learning framework for early target pharmacology assessment of biotherapeutics
Krutika Patidar, Nikhil Pillai, Saroj Dhakal, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights
Heidi M. Abdel-Mageed
Inflammopharmacology (2025)
Open Access
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 169-182
Open Access | Times Cited: 10
IL-13 inhibition in the treatment of atopic dermatitis – new and emerging biologic agents
Carlos Eduardo Garcez Teixeira, Orhan Yilmaz, Diana Bernardo, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 11
Open Access | Times Cited: 3
The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis
Agnieszka Hołdrowicz, Anna Woźniacka
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1754-1754
Open Access | Times Cited: 1
The Rebirth of Lebrikizumab for Airway Disease
Ian Pavord
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 5, pp. 1225-1227
Closed Access | Times Cited: 1
Development of a Minimal Physiologically-Based Pharmacokinetic Modeling / Machine Learning Framework for Early Target Pharmacology Assessment
Panteleimon D. Mavroudis, Krutika Patidar, Nikhil Pillai, et al.
Research Square (Research Square) (2024)
Open Access
Lebrikizumab▼: Short and Long-Term Disease Control in Moderate-to-Severe AD Through Selective IL-13 Inhibition
EMJ EMJ
European Medical Journal (2024), pp. 46-47
Open Access
Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study
Amita Datta‐Mannan, Brian Moser, Wen Xu, et al.
Clinical Therapeutics (2024)
Closed Access
Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis
Luca Stingeni, Silvia Ferrucci, Paolo Amerio, et al.
Expert Opinion on Biological Therapy (2024), pp. 1-6
Open Access
Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch, Marjolein de Bruin‐Weller, Marni Wiseman, et al.
Clinical and Experimental Dermatology (2024)
Closed Access
Page 1

Scroll to top